A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Launched by TAKEDA · May 29, 2024
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called recombinant ADAMTS13 for people with a rare condition known as congenital thrombotic thrombocytopenic purpura (cTTP). This condition affects how blood clots and can lead to serious health issues. The main goal of the study is to see if this treatment has any side effects and if it can help improve or prevent the symptoms of cTTP. Participants will receive the treatment through an intravenous injection, which means it will be given directly into their bloodstream, following the usual practices of their healthcare clinic.
Anyone with cTTP who is receiving treatment with recombinant ADAMTS13 can participate in the study. There are no specific exclusions, so if you meet this condition and are being treated, you might be eligible. During the study, doctors will monitor participants for any side effects over a period of 18 months. This is an important opportunity to learn more about how effective and safe this treatment is for those living with cTTP.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - All participants with congenital thrombotic thrombocytopenic purpura (cTTP), treated with recombinant ADAMTS13
- Exclusion Criteria:
- • - None
About Takeda
Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical organization committed to advancing patient care through innovative therapies. Founded in 1781 and headquartered in Osaka, Japan, Takeda focuses on key therapeutic areas including oncology, gastroenterology, neuroscience, and rare diseases. With a strong emphasis on research and development, Takeda leverages cutting-edge science and technology to deliver transformative medicines that address unmet medical needs. The company is dedicated to sustainability and ethical practices, ensuring that its clinical trials uphold the highest standards of safety and efficacy while fostering collaboration with healthcare professionals and communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Patients applied
Trial Officials
Study Director
Study Director
Takeda
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported